En Pilotundersøgelse, der Vurderer Tilsætning af β-hydroxybutyrat Samtidig med Kortvarig Strålebehandling Efterfulgt af Immunoterapi Kombineret med CAPEOX Neo-adjuvant Terapi hos Patienter med Lokalt Avanceret Endetarmskræft
En enkeltarmet, enkeltcenterundersøgelse af udforskning af β-hydroxybutyrat-tilskud og kortvarig stråleterapi efterfulgt af immunterapi kombineret med CAPEOX-neoadjuvantbehandling ved lokal fremskreden endetarmskræft
This study is a prospective phase II clinical trial aimed at exploring the potential benefits of supplementing β-hydroxybutyrate with existing short course radiotherapy sequential immunotherapy and CAPEOX therapy.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Zhenyu Lin, MD
- Telefonnummer: 027-83262683
- E-mail: whxhlzy@hust.edu.cn
Undersøgelse Kontakt Backup
- Navn: Tao Zhang, MD
- E-mail: whxhlzy@hust.edu.cn
Studiesteder
-
-
Hubei
-
Wuhan, Hubei, Kina, 430022
- Rekruttering
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Kontakt:
- Tao Zhang, MD
- Telefonnummer: 027-83262683
- E-mail: 1277577866@qq.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Patients or their family members agree to participate in the study and sign the informed consent form;
- Age 18-75 years, male or female;
- Histologically confirmed proficient mismatch repair (pMMR)/microsatellite-stable (MSS) LARC;
- Inferior margin ≤ 10 cm from the anal verge;
- ECOG performance status score is 0-1;
- Untreated with anti-tumor therapy for rectal cancer, including radiotherapy, chemotherapy, surgery, etc;
- There was no operative contraindication;
- Laboratory tests were required to meet the following requirements: White blood cell (WBC) ≥ 4×109/L; Absolute neutrophil count (ANC) ≥ 1.5×109/L; Platelet count ≥ 100×109/L; Hemoglobin ≥90 g/L; Serum total bilirubin ≤ 1.5 × upper limit of normal (ULN); Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; Serum creatinine ≤1.5 × ULN or creatinine clearance rate ≥ 50 mL/min; International normalized ratio (INR) ≤ 1.5 × ULN; Activated partial thromboplastin time (APTT) ≤ 1.5 × ULN;
- Urinary protein < 2+ or 24-hour urinary protein excretion < 1 g at baseline.
Exclusion Criteria:
- Patients with deficient mismatch repair (dMMR)/microsatellite instability-high (MSI-H) LARC;
- Subjects who have previously received any form of immunotherapy, including but not limited to immune checkpoint inhibitors, immune checkpoint agonists, immune cell therapy, or any other treatment targeting tumor immunomodulatory mechanisms;
- Presence of any concurrent disease or condition (including laboratory abnormalities), or any history of substance abuse or current evidence of such abuse, which, in the investigator's judgment, may compromise subject safety, interfere with the informed consent process, affect subject compliance, or confound the safety assessment of the investigational product.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: experimental group
Radiotherapy (SCRT): Total dose 25 Gy delivered in 5 fractions (5 Gy per fraction, once daily over 5 consecutive days). β-hydroxybutyrate: Oral β-hydroxybutyrate supplement (5g/day, starting from the day of first radiotherapy, lasting for 2 weeks). Immunotherapy (PD-1 monoclonal antibody): 200 mg via intravenous infusion every 3 weeks (q3w) for 6 cycles, initiated 1 week after radiotherapy completion. Chemotherapy (CAPEOX regimen): Oxaliplatin: 130 mg/m² IV infusion over 120 minutes on Day 1. Capecitabine: 1000 mg/m² orally twice daily (morning and evening, 30 minutes after meals) on Days 1-14. Cycle duration: 3 weeks per cycle; total of 6 cycles during the neoadjuvant phase. |
Eligible subjects will receive short-course radiotherapy (SCRT). One week after the end of treatment, subjects continued to receive neoadjuvant chemotherapy. 1000mg/m2, bid, po, d1-14,q3w 130mg/m2, ivgtt, d1,q3w The surgery was performed 1 week after the end of neoadjuvant therapy. Oral β-hydroxybutyrate supplement (5g/day, starting from the day of first radiotherapy, lasting for 2 weeks). |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
complete response (CR) rate
Tidsramme: an expected average of 12 months
|
Defined as pathological complete response (pCR) + Clinical complete response (cCR) |
an expected average of 12 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
3-year disease-Free Survival
Tidsramme: an expected average of 3 years
|
The time from the first day of disease free (operation date) to local or distant recurrence, or the death event caused by any reason, whichever occurs first |
an expected average of 3 years
|
|
Overall Survival
Tidsramme: an expected average of 5 years
|
The time from the date of randomization to the death caused by any cause |
an expected average of 5 years
|
|
Adverse events (AEs) were graded according to the NCI CTCAE version 5·0
Tidsramme: an expected average of 1.5 years
|
Adverse events and surgical safety |
an expected average of 1.5 years
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Ledende efterforsker: Zhenyu Lin, Huazhong University of Science and Technology Tongji Medical College Union Hospital
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Neoplasmer efter sted
- Neoplasmer
- Tarmsygdomme
- Gastrointestinale neoplasmer
- Neoplasmer i fordøjelsessystemet
- Sygdomme i fordøjelsessystemet
- Gastrointestinale sygdomme
- Kolorektale neoplasmer
- Intestinale neoplasmer
- Endetarmssygdomme
- Rektale neoplasmer
- Organiske kemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Nukleinsyrer, nukleotider og nukleosider
- Koordinationskomplekser
- Deoxycytidin
- Cytidin
- Pyrimidin -nukleosider
- Pyrimidiner
- Nukleosider
- Uracil
- Pyrimidinoner
- Deoxyribonucleosider
- Fluorouracil
- Capecitabin
- Oxaliplatin
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- Union-BHB
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .